ArticleVirchows Archiv : an international journal of pathology2026
Inflammatory gene expression profile of oral plasmablastic lymphoma.
Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plasmablastic lymphoma (PBL) is a rare and aggressive non-Hodgkin lymphoma with a poor prognosis and short survival rates. It is classified as a large B-cell lymphoma subtype, but carries a plasmacytic immunophenotype. Therefore, PBL has pathogenetic overlaps with diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) and plasma cell neoplasms (PCNs). Although recent studies have characterized important genetic abnormalities in PBL, the precise molecular mechanisms driving its pathogenesis remain elusive. In this study, we analyzed 607 inflammatory genes in 10 PBL, 11 DLBCL NOS/high-grade B-cell lymphoma (DLBCL NOS/HGBCL), and 11 PCN samples to uncover the PBL immunoregulatory landscape and to identify promising therapeutic target candidates. Several differentially expressed genes were observed, including STAT4, STAT5A, and MAPK14, with enriched pathways such as JAK-STAT, nuclear factor-kappa B (NF-κB), and complement signaling in the PBL group. Notably, CR2 was underexpressed in PBL compared to DLBCL NOS/HGBCL and PCNs, suggesting a restricted Wp latency stage of Epstein-Barr virus (EBV), which may contribute to immune evasion. Functional analyses identified key immune pathways, including cytokine-receptor interactions, Toll-like receptor signaling, and neutrophil extracellular trap formation, with protein-protein interaction networks, emphasizing complement activation and JAK-STAT signaling pathways. In conclusion, oral PBL exhibits a complex inflammatory gene expression profile, and key signaling pathways, particularly JAK-STAT, NF-κB, and complement activation, are enriched in this tumor compared to DLBCL NOS/HGBCL and PCNs.
Indexed as
Identifiers
40931234What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.